Cure My Disease

Don't miss your cure!

 Log in / Sign up

Non-Opioid pain drug tested for hysterectomy recovery

NCT ID NCT07836010

Symptom relief Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers at Duke University are studying whether adding suzetrigine, an oral non-opioid pain medication, to a standard multimodal pain relief plan helps women recovering from laparoscopic or robotic hysterectomy. The trial enrolls about 123 women aged 18 and older who are having this minimally invasive surgery. Investigators compare participants' opioid use and pain scores after leaving the recovery room with those of matched historical patients who received the standard regimen without suzetrigine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Suzetrigine, an oral non-opioid pain medication also known as Journavx
What this could lead to
If it works, adding suzetrigine could give women having minimally invasive hysterectomy a way to manage pain with fewer opioids.
What could go wrong
This is a single-center Phase 4 study comparing participants with historical controls rather than a randomized group, so results may not reflect a true cause-and-effect difference. Suzetrigine can interact with certain liver enzymes and may not be safe for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 123 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years presenting for a laparoscopic/robotic hysterectomy. * ASA Classification I-III. Exclusion Criteria: * Chronic pain or chronic opioid therapy. * Allergy or contraindication to any component of the multimodal analgesic regimen. * Need to convert to an open procedure. * Subjects with severe hepatic or renal impairment and those receiving CYP3A inhibitors. * Inability to communicate pain scores or need for analgesics. * Suspected or known addiction to or abuse of illicit drugs, prescription medicine(s) or alcohol within the past 2 years. * Psychiatric disorders that, in the opinion of the investigator, may interfere with study assessments or compliance. * Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course. * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postoperative pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.